nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

04.10.2016 | Letter to the Editor

¹⁷⁷Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response

verfasst von: Kambiz Rahbar, Martin Bögemann, Hojjat Ahmadzadehfar

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …

Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, et al. ¹⁷⁷Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3481-7.

Ahmadzadehfar H, Rahbar K, Kurpig S, Bogemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015. doi:10.1186/s13550-015-0114-2.

Ahmadzadehfar H, Eppard E, Kurpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with ¹⁷⁷Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016. doi:10.18632/oncotarget.7245.PubMedPubMedCentral

Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med. 2016.

Rahbar K, Bode A, Weckesser M, Avramovic N, Claesener M, Stegger L, et al. Radioligand therapy with ¹⁷⁷Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration-resistant prostate cancer. Clin Nucl Med. 2016. doi:10.1097/RLU.0000000000001240.

Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, Claesener M, Ahmadzadehfar H. Response and tolerability of a single dose of ¹⁷⁷Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016.

Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Prostate cancer clinical trials working group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol. 2008. doi:10.1200/JCO.2007.12.4487.

Lapa C, Werner RA, Bluemel C, Lueckerath K, Muegge DO, Strate A, et al. Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy. EJNMMI Res. 2014. doi:10.1186/s13550-014-0074-y.

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009. doi:10.2967/jnumed.108.057307.

Titel: 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
verfasst von: Kambiz Rahbar
Martin Bögemann
Hojjat Ahmadzadehfar
Publikationsdatum: 04.10.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3530-2

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma

Treatment response evaluation with 18F-FDG PET/CT and 18F-NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation

Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience

Short-term changes in arterial inflammation predict long-term changes in atherosclerosis progression

Do paraneoplastic changes in diffuse FDG organ uptake predict relapse? – Wait for confirmation study

Evaluation of bone-seeking novel radiotracer 68Ga-NO2AP-Bisphosphonate for the detection of skeletal metastases in carcinoma breast